secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001193125-23-026931
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics to cut ~84% of workforce, CEO Gardner departs; CFO Mahoney becomes President
--------------------------------------------------------------------------------

- Board approved restructuring plan reducing workforce by up to 56 positions (~84%), substantially complete by Feb 17, 2023.
- Expected severance and related costs of approximately $5.4 million by end of February 2023.
- CEO Jason Gardner, CTO David Nichols, CCO Caren Deardorf, CPO Kristen Stants, and SVP Shawn Rose to leave the company.
- CFO/COO Stephen Mahoney named President; Gardner resigns from board effective Feb 7, 2023.
- Preliminary cash, cash equivalents, and marketable securities of ~$112M as of Dec 31, 2022 (unaudited).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523026931/0001193125-23-026931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523026931/d434361d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-026931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer